BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP201/IR

* Kempharm receives clearance from FDA to initiate clinical

program for KP201/IR, a single-entity benzhydrocodone HCL

immediate release abuse-deterrent prodrug for the treatment of

acute pain

Read more